New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For TSM;ATHN;MPEL;RHHBY;DST;MCD;SYT;AKR;AET From The Last 14 Days
Check below for free stories on TSM;ATHN;MPEL;RHHBY;DST;MCD;SYT;AKR;AET the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
April 17, 2014
12:53 EDTAETOn The Fly: Midday Wrap
Subscribe for More Information
12:01 EDTTSMTSMC climbs after profit beats expectations
Subscribe for More Information
11:39 EDTTSMTSMC upgraded to Buy from Neutral at UBS
Subscribe for More Information
10:51 EDTAETHealth insurers slide after UnitedHealth results, cautious comments
Shares of a number of health insurers are falling after the largest company in the sector, UnitedHealth (UNH), reported slightly higher than expected first quarter profit but lower than expected revenue. WHAT'S NEW: UnitedHealth's first quarter earnings per share came in at $1.10, versus the consensus outlook of $1.09. The insurer reported revenue of $31.71B, compared with the consensus outlook of $31.99B. Taxes levied by the Affordable Care Act and weak funding of Medicare Advantage by the government weighed on UnitedHealth's earnings, the company stated. Also pushing down the company's earnings was "a very expensive," new Hepatitis C therapy, UnitedHealth stated on its earnings conference call. Hepatitis C treatments cost UnitedHealth hundreds of millions of dollars in the first quarter, the company stated, though it also noted that demand for the treatments should drop going forward as initial pent-up demand for them starts to decline. The company indicated that it was looking to be reimbursed by states for the money it is spending on hepatitis vaccines for Medicaid patients. Meanwhile, UnitedHealth reiterated its fiscal 2014 EPS guidance of $5.40-$5.60 and its fiscal 2014 revenue guidance of $128B-$129B. PRICE ACTION: In mid-morning trading, UnitedHealth sank 3.7% to $75.31. Other health insurers also declined, with WellPoint (WLP) dropping 4% to $91.89, Aetna (AET) falling 3.3% to $67.54, Humana (HUM) declining 2.25% to $106.35, and Health Net (HNT) sliding 1% to $31.74.
06:45 EDTTSMTSMC foresees sales exceeding projections on mobile demand, Bloomberg says
Subscribe for More Information
06:18 EDTRHHBYEMA warns that stolen Roche drug found on market
The European Medicines Agency has been informed that vials of the cancer medicine Herceptin, thought to have been stolen in Italy, including from hospitals, have been tampered with and re-introduced under false credentials into the supply chain in some countries. This is currently being investigated by Member State authorities and updates will be provided as more information becomes available. Italian law enforcement authorities are currently investigating the theft and are looking at whether other medicines may also be affected. No affected product has so far been identified at hospital level and there are no reports that any harm has come to patients in relation to the falsified medicine and authorities are working to avoid this. The marketing authorisation holder for Herceptin is Roche.
April 16, 2014
13:18 EDTSYTSyngenta downgraded to Neutral from Buy at Miller Tabak
Subscribe for More Information
10:08 EDTAETUnitedHealth retreats after Citi cuts rating on shares
Subscribe for More Information
07:32 EDTRHHBYRegeneron may be taking market share from Roche, says Brean Capital
Subscribe for More Information
06:59 EDTATHNathenahealth sell-off post Q1 would be buying opportunity, says Leerink
Leerink said it is "modestly worried" about athenahealth's bookings growth into the company's Q1 results on Thursday after the close. The firm would be a buyer of the stock on any potential weakness post earnings and maintains an Outperform rating on athenahealth with a $200 price target.
April 15, 2014
10:00 EDTATHNOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:02 EDTRHHBYRoche confirms FY outlook for low-to mid-single digit growth in sales
Subscribe for More Information
09:01 EDTRHHBYRoche reports Q1 sales CHF11.496B vs. CHF11.589B a year ago
Roche reported Q1 group sales rose 5% at constant exchange rates and fell 1% in Swiss francs compared to the prior year. Pharma sales were up 4%, with continued growth of Avastin, MabThera/Rituxan, Actemra/RoActemra and Herceptin compensating for expected decline in Xeloda sales, while Diagnostics division sales were up 7%. Roche CEO Severin Schwan said: “Both the Pharma and Diagnostics Divisions posted solid growth in the first quarter. I am particularly pleased with the strong uptake of our recently launched medicines Perjeta and Kadcyla for HER2-positive breast cancer."
08:23 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTRHHBYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTAET, RHHBYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
16:58 EDTATHNathenahealth reinstated with a Market Perform at Raymond James
Raymond James reinstated coverage of athenahealth with a Market Perform rating, down two notches from its previous rating of Strong Buy. The firm sees limited potential for positive earnings surprises.
April 11, 2014
10:05 EDTAETAetna, Tenet form accountable care collaboration in San Antonio
Aetna (AET), Tenet’s (THC) Baptist Health System and HealthTexas Medical Group announced an accountable care collaboration and the introduction of the Aetna Whole Health product in the San Antonio area. The health plans, designed for fully insured customers with employees who live or work in Bexar, Guadalupe, Comal and Kendall counties, will be available on July 1.
April 10, 2014
11:42 EDTRHHBYReport claims Tamiflu, Relenza do little to prevent the spread of flu
Subscribe for More Information
10:24 EDTMPELMGM holds up amid broader downtrend after analyst recommends stock
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use